Fields Adam C, Melnitchouk Nelya, Senturk James, Irani Jennifer, Bleday Ronald, Goldberg Joel
Department of Surgery, Division of Colorectal Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
J Surg Oncol. 2019 Aug;120(2):287-293. doi: 10.1002/jso.25489. Epub 2019 May 4.
BACKGROUND/OBJECTIVES: The first-line treatment for anal squamous cell carcinoma is Nigro protocol chemoradiotherapy. Some patients will fail curative intent chemoradiotherapy and have persistent disease while others may have an initial response followed by disease recurrence. The goal of this study is to investigate survival in anal squamous cell carcinoma patients who fail first-line treatment.
The National Cancer Database (2004-2013) was used to identify patients with anal squamous cell carcinoma. The primary outcome was overall survival.
There were 256 patients in the early salvage group who underwent abdominoperineal resection (APR) within 6 months of completing chemoradiotherapy and 181 patients in the late salvage group who had APR 6 months or more after completion of chemoradiotherapy. Both groups of patients had similar tumor size (45 vs 50 mm; P = 0.07) and rate of positive margins (21.5% vs 15.6%;P = 0.13). There was no significant difference in overall survival between early and late salvage APR (hazard ratio [HR]: 0.81; 95% confidence interval [CI]: 0.50-1.32; P = 0.40).
The overall survival of anal squamous cell carcinoma patients undergoing early vs late salvage APR after failure of chemoradiotherapy is similar. As a result, patients with persistent disease should be offered surgery just as readily as those with recurrent disease.
背景/目的:肛门鳞状细胞癌的一线治疗是Nigro方案放化疗。一些患者的根治性放化疗会失败且疾病持续存在,而另一些患者可能最初有反应但随后疾病复发。本研究的目的是调查一线治疗失败的肛门鳞状细胞癌患者的生存率。
使用国家癌症数据库(2004 - 2013年)来识别肛门鳞状细胞癌患者。主要结局是总生存期。
早期挽救组有256例患者在完成放化疗后6个月内接受了腹会阴联合切除术(APR),晚期挽救组有181例患者在完成放化疗6个月或更长时间后接受了APR。两组患者的肿瘤大小相似(45 vs 50mm;P = 0.07),切缘阳性率也相似(21.5% vs 15.6%;P = 0.13)。早期和晚期挽救性APR的总生存期无显著差异(风险比[HR]:0.81;95%置信区间[CI]:0.50 - 1.32;P = 0.40)。
放化疗失败后接受早期或晚期挽救性APR的肛门鳞状细胞癌患者的总生存期相似。因此,疾病持续存在的患者应与疾病复发的患者一样容易获得手术治疗。